Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in P53-Mutated Ovarian and Endometrial Cancer
NCT04489706Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jun 2020
- Primary completion
- Nov 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of arsenic trioxide in ovarian cancer and endometrial cancer (EC), sponsored by Ruijin Hospital. Primary endpoints: Objective Response Rate at 1 year and Serum Tumor Marker Levels at 1 year. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT04489706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489706.